In a phase III clinical trial the New England Journal of Medicine, published the drug, Lecanemab slows the rate of cognitive decline by 27% in patients in the early stages of Alzheimer's. Researchers followed nearly 1,800 patients over the course of 18 months. For more details click on link below: